A Phase 2 interventional study of PF-06823859 low and Placebo Arm in Dermatomyositis, sponsored by Pfizer. Completed at 41 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-09-14.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Dermatomyositis with a site in United States — 30 open to participants now, 33 under way, 6 of them phase 3. Dermatomyositis · United States.
Among the 94 studies in Dermatomyositis with a site in United States, this one is the 21st largest by enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2018, is one of 31 in phase 2, and was the 42nd registered.
184 studies on the registry are indexed under Dermatomyositis; 63 are open to participants now.
Browse Dermatomyositis studies →30 of the 94 studies in Dermatomyositis with a site in United States are open now. Recruiting first, the newest first:
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 18–62
Fate Therapeutics · Sites in United States
Ages 18–70
University of Miami · Sites in United States
Ages 18+
Cartesian Therapeutics · Sites in United States
Ages 12+
Restem, LLC. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 50 Dermatomyositis studies recruiting now, 24 (48%) set no upper age limit and 16 (32%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 42 · Phase 3 17 · Phase 4 2
First in 1990; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is above the median of 35 across 130 interventional studies indexed under Dermatomyositis.
Median enrollment 25 across the 73 interventional studies, 540 across the 18 observational. Of the 55 that completed or were terminated, 26 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 94 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 4 studies filed under Dermatomyositis — fewer than ten, so there is no comparison to draw.
5 of the studies in Dermatomyositis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06284954argenxA Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis | 2026-11 |
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
| NCT06298019Stanford UniversityStudy of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis | 2027-04 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT07486869University of MiamiEmapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 94 studies in Dermatomyositis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Study looking at Investigational drug and Placebo administered to adult Patients with moderate to severe Dermatomyositis
Inclusion Criteria for Patients with Skin Predominant Activity:
Confirmation of DM by the investigator and two of the following:
Inclusion Criteria for Patients with Muscle Predominant Activity:
Sum of PhGA, VAS, PtGA, and extramuscular global assessment VAS scores is ≥10 cm (0-10 cm) VAS for each.
Exclusion Criteria for Patients with Skin Predominant Activity:
Exclusion Criteria for Patients with Muscle Predominant Activity:
Similar to patients with skin predominant activity; Intake of >20 mg oral prednisone/day, or equivalent
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo Arm
Drug: PF-06823859 high
Drug: PF-06823859 low
A humanized immunoglobulin neutralizing antibody
Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid
A humanized immunoglobulin neutralizing antibody
Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2)
The treatment effect was defined as the difference (mean chg from baseline at Week12 in the active treatment group minus that in the placebo group) in the mean change of CDASI activity score from baseline at Week 12. The score (range: 0-100) consists of the extent score (ES), Gottorn hands score (GHS), peringual score (PS) and allopecia score (AS). ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\], peeling of the skin) and erosion/ulceration (EU \[0-15\], presence of the deeper wound). Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body. GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1). PS (0-2) characterizes abnormalities around nails. The AS (0-1) characterizes hair loss. Higher scores indicate greater disease severity.
Time frame: Baseline and Week 12
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) (Stage 3)
Adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose resulted in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. AEs included both serious (if occurred) and all non-serious adverse events. TEAEs are events between first dose of study drug and up to Week 40 that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Up to Week 40
Number of Participants With Clinically Significant Laboratory Abnormalities (Stage 3)
Hemoglobin(HGB),hematocrit,erythrocytes(ery.),HDL cholesterol(chl.)\<0.8\*lower limit of normal(LLN);reticulocytes (ret.), ret./ery.(%)\<0.5\*LLN,\>1.5\*upper limit of normal (ULN);ery. mean corpuscular(EMC) volume,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN; leukocytes(leu.),glucose\<0.6\*LLN,\>1.5\*ULN;lymphocytes(lym.), lym./leu.(%),neutrophils (neu.), neu./leu.(%), protein,albumin\<0.8\*LLN,\>1.2\*ULN;basophils(bas.), bas./leu.(%), eosinophils(eos.), eos./leu., monocytes(mon.), mon./leu.(%), urate\>1.2\*ULN;bilirubin (total, direct,indirect)\>1.5\*ULN;aspartate/alanine aminotransferase,gamma glutamyl transferase,lactate dehydrogenase,alkaline phosphatase\>3.0\*ULN;urea nitrogen,creatinine,triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones,protein, HGB,urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20.
Time frame: Up to Week 40
Number of Participants With Vital Sign Abnormalities (Stage 3)
Abnormality in vital signs: Sitting pulse rate \<40 beats per minute (bpm) to \>120 bpm, sitting diastolic blood pressure (DBP) \< 50 millimeter of mercury (mmHg), sitting systolic blood pressure (SBP) \<90 mmHg.
Time frame: Baseline up to Week 40
Number of Participants With Electrocardiogram (ECG) Abnormalities (Stage 3)
ECG abnormalities criteria included: 1) QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>=30, increase from baseline \>=60; 2) Pulse rate (PR) (msec): \>=300, change from baseline (Chg) \>=25% or 50%; 3) QT (msec): \>=500; 4) QRS (msec): \>=200, Chg \>=25% or 50%. Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure.
Time frame: Baseline up to Week 40
Number of Participants With TEAEs and SAEs (Stage 1 and Stage 2)
AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose resulted in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. AEs included both serious (if occurred) and all non-serious adverse events. TEAEs are events between first dose of study drug and up to Week 28 that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Up to Week 28
Number of Participants With TEAEs and SAEs (Amended Stage 2)
AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose resulted in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. AEs included both serious (if occurred) and all non-serious adverse events. TEAEs are events between first dose of study drug and up to Week 40 that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Up to Week 40
Number of Participants With Clinically Significant Laboratory Abnormalities (Stage 1 and Stage 2)
HGB,hematocrit,ery.,HDL chl.\<0.8\*LLN;ret., ret./ery. (%)\<0.5\*LLN,\>1.5\*ULN;EMC volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN;leu.,glucose\<0.6\*LLN,\>1.5\*ULN;lym., lym./leu.(%), neu., neu./leu. (%), protein,albumin \<0.8\*LLN,\>1.2\*ULN;bas., bas./leu.(%), eos., eos./leu., mon., mon./leu.(%), urate \>1.2\*ULN;bilirubin (total, direct, indirect)\>1.5\*ULN;aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase\>3.0\*ULN;urea nitrogen, creatinine, triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20. Clinical significance of laboratory parameters was determined at the investigator's discretion.
Time frame: Up to Week 28
Number of Participants With Clinically Significant Laboratory Abnormalities (Amended Stage 2)
HGB,hematocrit,ery.,HDL chl.\<0.8\*LLN;ret., ret./ery. (%)\<0.5\*LLN,\>1.5\*ULN;EMC volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN;leu.,glucose\<0.6\*LLN,\>1.5\*ULN;lym., lym./leu.(%), neu., neu./leu. (%), protein,albumin \<0.8\*LLN,\>1.2\*ULN;bas., bas./leu.(%), eos., eos./leu., mon., mon./leu.(%), urate \>1.2\*ULN;bilirubin (total, direct, indirect)\>1.5\*ULN;aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase\>3.0\*ULN;urea nitrogen, creatinine, triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20. Clinical significance of laboratory parameters was determined at the investigator's discretion.
Time frame: Up to Week 40
Number of Participants With Vital Sign Abnormalities (Stage 1 and Stage 2)
Abnormality in vital signs: Sitting pulse rate \<40 bpm to \>120 bpm, sitting DBP \< 50 mmHg, sitting SBP \<90 mmHg.
Time frame: Up to Week 28
Number of Participants With Vital Sign Abnormalities (Amended Stage 2)
Abnormality in vital signs: Sitting pulse rate \<40 bpm to \>120 bpm, sitting DBP \< 50 mmHg, sitting SBP \<90 mmHg.
Time frame: Up to Week 40
Number of Participants With ECG Abnormalities (Stage 1 and Stage 2)
ECG abnormalities criteria included: 1) QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>=30, increase from baseline \>=60; 2) Pulse rate (PR) (msec): \>=300, change from baseline (Chg) \>=25% or 50%; 3) QT (msec): \>=500; 4) QRS (msec): \>=200, Chg \>=25% or 50%. Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure.
Time frame: Up to Week 28
Number of Participants With ECG Abnormalities (Amended Stage 2)
ECG abnormalities criteria included: 1) QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>=30, increase from baseline \>=60; 2) Pulse rate (PR) (msec): \>=300, change from baseline (Chg) \>=25% or 50%; 3) QT (msec): \>=500; 4) QRS (msec): \>=200, Chg \>=25% or 50%. Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure.
Time frame: Up to Week 40
Change From Baseline in CDASI Activity Score at at All Scheduled Timepoints Through Week 12 (Stage 1, Stage 2 and Amended Stage 2)
The treatment effect was defined as the difference (mean change from baseline at Weeks 1, 4, 8 in the active treatment group minus the mean change from baseline at Weeks 1, 4, 8 in the placebo group) in the mean change of CDASI activity score from baseline at scheduled timepoints. The score (range: 0-100) consists of the ES, GHS, PS and AS. ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\], peeling of the skin) and erosion/ulceration (EU \[0-15\], presence of the deeper wound). Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body. GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1). PS (0-2) characterizes abnormalities around nails. The AS (0-1) characterizes hair loss. Higher scores indicate greater disease severity.
Time frame: Baseline, Week 1, Week 4, and Week 8 (except for Week 12 which is a primary outcome measure)
Change From Baseline in CDASI Activity Score at All Scheduled Timepoints Through Week 12 (Stage 3)
The treatment effect was defined as the difference (mean change from baseline at Weeks 1, 4, 8,12 in the active treatment group minus the mean change from baseline at Weeks 1, 4, 8, 12 in the placebo group) in the mean change of CDASI activity score from baseline at scheduled timepoints. The score (range: 0-100) consists of the ES, GHS, PS and AS. ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\], peeling of the skin) and erosion/ulceration (EU \[0-15\], presence of the deeper wound). Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body. GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1). PS (0-2) characterizes abnormalities around nails. The AS (0-1) characterizes hair loss. Higher scores indicate greater disease severity.
Time frame: Baseline, Week 1, Week 4, Week 8 and Week 12
Absolute Values of CDASI Activity Score at All Scheduled Timepoints Through Week 12 (All Stages)
The CDASI activity score (range: 0-100) consists of the ES, GHS, PS and AS. ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\], peeling of the skin) and erosion/ulceration (EU \[0-15\], presence of the deeper wound). Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body. GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1). PS (0-2) characterizes abnormalities around nails. The AS (0-1) characterizes hair loss. Higher scores indicate greater disease severity.
Time frame: Baseline, Week 1, Week 4, Week 8 and Week 12
Absolute Values of CDASI Damage Score at All Scheduled Timepoints Through Week 12 (All Stages)
The Damage Score (DS) was calculated as a sum of the total poilkiloderma score (POLS), total calcinosis score (CALS) and Gotorn's hands damage score (GHDS). The POLS characterizes specific dispigmentation in the particulal area and calcinosis score characterizes calcification of the skin in the particular area. The POLS and the CALS are summed up over 15 individual areas in the body and each of them has range 0-15. The GHDS has the range 0-2 so that the DS has the range 0-32. Higher scores indicate greater disease severity.
Time frame: Baseline, Week 1, Week 4, Week 8 and Week 12
Absolute Values for Total Improvement Score (TIS) at Week 12 and Intermediate Scheduled Time Points (Stage 3)
The TIS was the sum of all 6 improvement scores where higher score indicates worse status (PhGA \[from the MDAAT, 0-20 scale\], PtGA \[0-10 scale\], MMT \[0-35 scale\], HAQ-DI \[0-10 scale\], muscle enzymes \[0-7.5 scale\], and extramuscular global assessment \[0-20 scale\]) associated with the change in each core set measure. A total improvement score between 0 and 100 corresponded to the degree of improvement, with higher scores corresponding to a greater degree of improvement: of ≥20 represented minimal improvement, a score of ≥40 represented moderate improvement, and a score of ≥60 represented major improvement.
Time frame: Week 4, Week 8 and Week 12
Change From Baseline in the Core Set Measures (CSM) of the TIS (Global Disease Activity [PhGA] and Extramuscular Global Assessment [EmGA]) (Stage 3)
PhGA: assessment of the severity of disease by the physician. The physician used the visual analog scale and put a mark on 0 cm (best) -10 cm (worst) scale where higher score indicated worse status. EmGA: overall evaluation of disease activity in all extramuscular systems using visual analog scale 0 cm (best) -10 cm (worst) scale where higher score indicated worse status.
Time frame: Baseline, Week 4, Week 8 and Week 12
Change From Baseline in the CSM of the TIS (PtGA) (Stage 3)
PtGA: assessment of the severity of disease by the participant/participant's guardian, using a visual analog scale from 0 mm (no evidence of disease activity) to 100 mm (extremely active or severe disease activity). Higher score indicated worse status.
Time frame: Baseline, Week 4, Week 8 and Week 12
Change From Baseline in the CSM of the TIS (MMT8 and HAQ01-HAQ-DI) (Stage 3)
Manual Muscle Testing-8 designated muscle groups (MMT-8): was a set of 8 designated muscles tested unilaterally generally on right side (left side used unless right side cannot be used). Potential score range was from 0 to 80, where higher scores denoted better health status. HAQ-DI: contained eight sections (including dressing \& grooming, arising, eating, walking, hygiene, grip, reach, and activities). Each section had multiple questions that the participant used to rank their functionality and ranged from 0 to 3 where 0 = without any difficulty and 3 = unable to do. For each participant, the average ranking was calculated for each of the eight sections. HAQ-DI had a score range of 0 to 3, where higher score reflected worse status.
Time frame: Week 4, Week 8 and Week 12
Change From Baseline in the CSM of the TIS (Aldolase and Creatine Kinase) (Stage 3)
The LS mean (with 90% CI) of CSM of the TIS (aldolase and creatine kinase) at weeks 4, 8, 12 were presented.
Time frame: Baseline, Week 4, Week 8 and Week 12
| Milestone | (Stage 1) Placebo | (Stage 1) PF-06823859 600 mg Intravenous (IV) | (Stage 2) Placebo | (Stage 2) PF-06823859 150 mg IV | (Stage 2) PF-06823859 600 mg IV | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 10 | 22 | 1 | 5 | 3 | 2 | 1 | 10 | 3 | 9 | 9 |
| Completed | 9 | 20 | 1 | 5 | 3 | 2 | 1 | 10 | 3 | 9 | 9 |
| Not completed | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | (Stage 1) Placebo | (Stage 1) PF-06823859 600 mg Intravenous (IV) | (Stage 2) Placebo | (Stage 2) PF-06823859 150 mg IV | (Stage 2) PF-06823859 600 mg IV | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 10 | 3 | 9 | 9 |
| Completed | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 9 | 2 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
The treatment effect was defined as the difference (mean chg from baseline at Week12 in the active treatment group minus that in the placebo group) in the mean change of CDASI activity score from baseline at Week 12. The score (range: 0-100) consists of the extent score (ES), Gottorn hands score (GHS), peringual score (PS) and allopecia score (AS). ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\], peeling of the skin) and erosion/ulceration (EU \[0-15\], presence of the deeper wound). Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body. GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1). PS (0-2) characterizes abnormalities around nails. The AS (0-1) characterizes hair loss. Higher scores indicate greater disease severity.
| Units on a scale | (Stage 1) Placebo | PF-06823859 600 mg IV (Stage 1) | (Stage 2) Placebo | (Stage 2) PF-06823859 150 mg IV | (Stage 2) PF-06823859 600 mg IV | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2) | -3.44 ± 5.270 | -19.62 ± 9.140 | 5.00 | -17.40 ± 9.290 | -26.00 ± 7.937 | -3.00 ± 8.485 | 3.00 | -16.40 ± 5.835 | -15.33 ± 6.028 |
Adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose resulted in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. AEs included both serious (if occurred) and all non-serious adverse events. TEAEs are events between first dose of study drug and up to Week 40 that were absent before treatment or that worsened relative to pretreatment state.
| Participants | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 |
|---|---|---|
| TEAEs | 7 | 8 |
| SAEs | 0 | 2 |
Hemoglobin(HGB),hematocrit,erythrocytes(ery.),HDL cholesterol(chl.)\<0.8\*lower limit of normal(LLN);reticulocytes (ret.), ret./ery.(%)\<0.5\*LLN,\>1.5\*upper limit of normal (ULN);ery. mean corpuscular(EMC) volume,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN; leukocytes(leu.),glucose\<0.6\*LLN,\>1.5\*ULN;lymphocytes(lym.), lym./leu.(%),neutrophils (neu.), neu./leu.(%), protein,albumin\<0.8\*LLN,\>1.2\*ULN;basophils(bas.), bas./leu.(%), eosinophils(eos.), eos./leu., monocytes(mon.), mon./leu.(%), urate\>1.2\*ULN;bilirubin (total, direct,indirect)\>1.5\*ULN;aspartate/alanine aminotransferase,gamma glutamyl transferase,lactate dehydrogenase,alkaline phosphatase\>3.0\*ULN;urea nitrogen,creatinine,triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones,protein, HGB,urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20.
| Participants | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 |
|---|---|---|
| Number of Participants With Clinically Significant Laboratory Abnormalities (Stage 3) | 0 | 1 |
Abnormality in vital signs: Sitting pulse rate \<40 beats per minute (bpm) to \>120 bpm, sitting diastolic blood pressure (DBP) \< 50 millimeter of mercury (mmHg), sitting systolic blood pressure (SBP) \<90 mmHg.
| Participants | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 |
|---|---|---|
| Sitting SBP Value <90 mmHg | 0 | 0 |
| Sitting DBP Value <50 mmHg | 0 | 0 |
| Sitting Pulse Rate Value <40 bpm | 0 | 0 |
| Sitting Pulse Rate Value >120 bpm | 0 | 0 |
ECG abnormalities criteria included: 1) QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>=30, increase from baseline \>=60; 2) Pulse rate (PR) (msec): \>=300, change from baseline (Chg) \>=25% or 50%; 3) QT (msec): \>=500; 4) QRS (msec): \>=200, Chg \>=25% or 50%. Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure.
| Participants | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 |
|---|---|---|
| PR Interval Aggregate Value >=300 msec | 0 | 0 |
| QRS Duration Aggregate Value >=200 msec | 0 | 0 |
| QT Interval Aggregate Value >=500 msec | 0 | 0 |
| QTcF Interval Aggregate 450<=Value<480 msec | 0 | 1 |
| QTcF Interval Aggregate 480<=Value<500 msec | 1 | 0 |
| QTcF Interval Aggregate Value >=500 msec | 0 | 0 |
| PR %Chg >=25% or >=50% | 0 | 0 |
| QRS Duration %Chg >=25% or >=50% | 0 | 0 |
| 30<=QTcF Chg (msec)<60 | 0 | 0 |
| QTcF Chg (msec) >=60 | 0 | 1 |
AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose resulted in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. AEs included both serious (if occurred) and all non-serious adverse events. TEAEs are events between first dose of study drug and up to Week 28 that were absent before treatment or that worsened relative to pretreatment state.
| Participants | (Stage 1) Placebo | PF-06823859 600 mg IV (Stage 1) | (Stage 2) Placebo | (Stage 2) PF-06823859 150 mg IV | (Stage 2) PF-06823859 600 mg IV |
|---|---|---|---|---|---|
| TEAEs | 8 | 20 | 1 | 5 | 3 |
| SAEs | 1 | 2 | 0 | 0 | 0 |
AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose resulted in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. AEs included both serious (if occurred) and all non-serious adverse events. TEAEs are events between first dose of study drug and up to Week 40 that were absent before treatment or that worsened relative to pretreatment state.
| Participants | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 |
|---|---|---|---|---|
| TEAEs | 1 | 1 | 8 | 3 |
| SAEs | 0 | 0 | 0 | 0 |
HGB,hematocrit,ery.,HDL chl.\<0.8\*LLN;ret., ret./ery. (%)\<0.5\*LLN,\>1.5\*ULN;EMC volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN;leu.,glucose\<0.6\*LLN,\>1.5\*ULN;lym., lym./leu.(%), neu., neu./leu. (%), protein,albumin \<0.8\*LLN,\>1.2\*ULN;bas., bas./leu.(%), eos., eos./leu., mon., mon./leu.(%), urate \>1.2\*ULN;bilirubin (total, direct, indirect)\>1.5\*ULN;aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase\>3.0\*ULN;urea nitrogen, creatinine, triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20. Clinical significance of laboratory parameters was determined at the investigator's discretion.
| Participants | (Stage 1) Placebo | PF-06823859 600 mg IV (Stage 1) | (Stage 2) Placebo | (Stage 2) PF-06823859 150 mg IV | (Stage 2) PF-06823859 600 mg IV |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Laboratory Abnormalities (Stage 1 and Stage 2) | 0 | 0 | 0 | 0 | 0 |
HGB,hematocrit,ery.,HDL chl.\<0.8\*LLN;ret., ret./ery. (%)\<0.5\*LLN,\>1.5\*ULN;EMC volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN;leu.,glucose\<0.6\*LLN,\>1.5\*ULN;lym., lym./leu.(%), neu., neu./leu. (%), protein,albumin \<0.8\*LLN,\>1.2\*ULN;bas., bas./leu.(%), eos., eos./leu., mon., mon./leu.(%), urate \>1.2\*ULN;bilirubin (total, direct, indirect)\>1.5\*ULN;aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase\>3.0\*ULN;urea nitrogen, creatinine, triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20. Clinical significance of laboratory parameters was determined at the investigator's discretion.
| Participants | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Laboratory Abnormalities (Amended Stage 2) | 0 | 0 | 0 | 0 |
Abnormality in vital signs: Sitting pulse rate \<40 bpm to \>120 bpm, sitting DBP \< 50 mmHg, sitting SBP \<90 mmHg.
| Participants | (Stage 1) Placebo | PF-06823859 600 mg IV (Stage 1) | (Stage 2) Placebo | (Stage 2) PF-06823859 150 mg IV | (Stage 2) PF-06823859 600 mg IV |
|---|---|---|---|---|---|
| Sitting SBP Value <90 mmHg | 0 | 1 | 0 | 0 | 0 |
| Sitting DBP Value <50 mmHg | 0 | 0 | 0 | 0 | 0 |
| Sitting Pulse Rate Value <40 bpm | 0 | 0 | 0 | 0 | 0 |
| Sitting Pulse Rate Value >120 bpm | 0 | 0 | 0 | 0 | 0 |
Abnormality in vital signs: Sitting pulse rate \<40 bpm to \>120 bpm, sitting DBP \< 50 mmHg, sitting SBP \<90 mmHg.
| Participants | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 |
|---|---|---|---|---|
| Sitting SBP Value <90 mmHg | 0 | 0 | 0 | 0 |
| Sitting DBP Value <50 mmHg | 0 | 0 | 0 | 0 |
| Sitting Pulse Rate Value <40 bpm | 0 | 0 | 0 | 0 |
| Sitting Pulse Rate Value >120 bpm | 0 | 0 | 0 | 0 |
ECG abnormalities criteria included: 1) QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>=30, increase from baseline \>=60; 2) Pulse rate (PR) (msec): \>=300, change from baseline (Chg) \>=25% or 50%; 3) QT (msec): \>=500; 4) QRS (msec): \>=200, Chg \>=25% or 50%. Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure.
| Participants | (Stage 1) Placebo | PF-06823859 600 mg IV (Stage 1) | (Stage 2) Placebo | (Stage 2) PF-06823859 150 mg IV | (Stage 2) PF-06823859 600 mg IV |
|---|---|---|---|---|---|
| PR Interval Aggregate Value >=300 msec | 0 | 0 | 0 | 0 | 0 |
| QRS Duration Aggregate Value >=200 msec | 0 | 0 | 0 | 0 | 0 |
| QT Interval Aggregate Value >=500 msec | 0 | 0 | 0 | 0 | 0 |
| QTcF Interval Aggregate 450<=Value<480 msec | 3 | 1 | 0 | 1 | 0 |
| QTcF Interval Aggregate 480<=Value<500 msec | 0 | 0 | 0 | 0 | 0 |
| QTcF Interval Aggregate Value >=500 msec | 0 | 1 | 0 | 0 | 0 |
| PR %Chg >=25% or >=50% | 0 | 0 | 0 | 0 | 0 |
| QRS Duration %Chg >=25% or >=50% | 0 | 0 | 0 | 0 | 0 |
| 30<=QTcF Chg (msec)<60 | 0 | 0 | 0 | 0 | 0 |
| QTcF Chg (msec) >=60 | 0 | 1 | 0 | 0 | 0 |
ECG abnormalities criteria included: 1) QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>=30, increase from baseline \>=60; 2) Pulse rate (PR) (msec): \>=300, change from baseline (Chg) \>=25% or 50%; 3) QT (msec): \>=500; 4) QRS (msec): \>=200, Chg \>=25% or 50%. Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure.
| Participants | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 |
|---|---|---|---|---|
| PR Interval Aggregate Value >=300 msec | 0 | 0 | 0 | 0 |
| QRS Duration Aggregate Value >=200 msec | 0 | 0 | 0 | 0 |
| QT Interval Aggregate Value >=500 msec | 0 | 0 | 0 | 0 |
| QTcF Interval Aggregate 450<=Value<480 msec | 1 | 0 | 3 | 0 |
| QTcF Interval Aggregate 480<=Value<500 msec | 0 | 0 | 0 | 0 |
| QTcF Interval Aggregate Value >=500 msec | 0 | 0 | 0 | 0 |
| PR %Chg >=25% or >=50% | 0 | 0 | 0 | 0 |
| QRS Duration %Chg >=25% or >=50% | 0 | 0 | 0 | 0 |
| 30<=QTcF Chg (msec)<60 | 1 | 0 | 1 | 0 |
| QTcF Chg (msec) >=60 | 0 | 0 | 0 | 0 |
The treatment effect was defined as the difference (mean change from baseline at Weeks 1, 4, 8 in the active treatment group minus the mean change from baseline at Weeks 1, 4, 8 in the placebo group) in the mean change of CDASI activity score from baseline at scheduled timepoints. The score (range: 0-100) consists of the ES, GHS, PS and AS. ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\], peeling of the skin) and erosion/ulceration (EU \[0-15\], presence of the deeper wound). Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body. GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1). PS (0-2) characterizes abnormalities around nails. The AS (0-1) characterizes hair loss. Higher scores indicate greater disease severity.
| Units on a scale | (Stage 1) Placebo | PF-06823859 600 mg IV (Stage 1) | (Stage 2) Placebo | (Stage 2) PF-06823859 150 mg IV | (Stage 2) PF-06823859 600 mg IV | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 |
|---|---|---|---|---|---|---|---|---|---|
| Week 1 | -2.60 ± 4.326 | -19.62 ± 9.140 | 1.00 | -9.80 ± 12.174 | -2.33 ± 1.528 | -6.50 ± 6.364 | 0.00 | -8.70 ± 5.638 | -6.67 ± 2.517 |
| Week 4 | -2.44 ± 8.126 | -12.00 ± 10.277 | 3.00 | -11.20 ± 10.986 | -15.00 ± 7.550 | -3.00 ± 7.071 | -1.00 | -14.40 ± 7.648 | -14.00 ± 2.000 |
| Week 8 | -4.22 ± 6.942 | -17.19 ± 9.595 | 4.00 | -14.20 ± 5.020 | -18.67 ± 10.066 | -2.50 ± 7.778 | -2.00 | -17.80 ± 7.540 | -14.00 ± 4.000 |
The treatment effect was defined as the difference (mean change from baseline at Weeks 1, 4, 8,12 in the active treatment group minus the mean change from baseline at Weeks 1, 4, 8, 12 in the placebo group) in the mean change of CDASI activity score from baseline at scheduled timepoints. The score (range: 0-100) consists of the ES, GHS, PS and AS. ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\], peeling of the skin) and erosion/ulceration (EU \[0-15\], presence of the deeper wound). Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body. GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1). PS (0-2) characterizes abnormalities around nails. The AS (0-1) characterizes hair loss. Higher scores indicate greater disease severity.
| Units on a scale | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 |
|---|---|---|
| Week 1 | -2.00 ± 3.808 | -2.11 ± 2.522 |
| Week 4 | -3.78 ± 5.333 | -5.11 ± 5.555 |
| Week 8 | -5.00 ± 7.382 | -7.78 ± 6.667 |
| Week 12 | -5.89 ± 8.177 | -8.56 ± 7.923 |
The CDASI activity score (range: 0-100) consists of the ES, GHS, PS and AS. ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\], peeling of the skin) and erosion/ulceration (EU \[0-15\], presence of the deeper wound). Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body. GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1). PS (0-2) characterizes abnormalities around nails. The AS (0-1) characterizes hair loss. Higher scores indicate greater disease severity.
| Units on a scale | (Stage 1) Placebo | PF-06823859 600 mg IV (Stage 1) | (Stage 2) Placebo | (Stage 2) PF-06823859 150 mg IV | (Stage 2) PF-06823859 600 mg IV | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 31.50 ± 11.750 | 33.23 ± 10.323 | 23.00 | 28.60 ± 9.017 | 37.00 ± 9.644 | 26.00 ± 5.657 | 37.00 | 35.40 ± 13.226 | 30.00 ± 7.937 | 17.22 ± 11.595 | 12.56 ± 8.095 |
| Week 1 | 28.90 ± 12.982 | 27.68 ± 8.962 | 24.00 | 18.80 ± 6.535 | 34.67 ± 9.713 | 19.50 ± 0.707 | 37.00 | 26.70 ± 12.667 | 23.33 ± 9.018 | 15.22 ± 9.846 | 10.44 ± 6.894 |
| Week 4 | 28.11 ± 16.136 | 21.23 ± 11.182 | 26.00 | 17.40 ± 2.408 | 22.00 ± 12.490 | 23.00 ± 1.414 | 36.00 | 21.00 ± 10.677 | 16.00 ± 9.539 | 13.44 ± 8.819 | 7.44 ± 5.503 |
| Week 8 | 26.33 ± 13.892 | 15.29 ± 6.157 | 27.00 | 14.40 ± 5.857 | 18.33 ± 5.508 | 23.50 ± 2.121 | 35.00 | 17.60 ± 10.895 | 16.00 ± 11.269 | 12.22 ± 10.883 | 4.78 ± 4.116 |
| Week 12 | 27.11 ± 14.903 | 12.86 ± 5.876 | 28.00 | 11.20 ± 4.817 | 11.00 ± 3.464 | 23.00 ± 2.828 | 40.00 | 19.00 ± 14.087 | 14.67 ± 9.504 | 11.33 ± 9.206 | 4.00 ± 3.464 |
The Damage Score (DS) was calculated as a sum of the total poilkiloderma score (POLS), total calcinosis score (CALS) and Gotorn's hands damage score (GHDS). The POLS characterizes specific dispigmentation in the particulal area and calcinosis score characterizes calcification of the skin in the particular area. The POLS and the CALS are summed up over 15 individual areas in the body and each of them has range 0-15. The GHDS has the range 0-2 so that the DS has the range 0-32. Higher scores indicate greater disease severity.
| Units on a scale | (Stage 1) Placebo | PF-06823859 600 mg IV (Stage 1) | (Stage 2) Placebo | (Stage 2) PF-06823859 150 mg IV | (Stage 2) PF-06823859 600 mg IV | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 4.30 ± 5.397 | 5.50 ± 3.901 | 3.00 | 4.20 ± 3.701 | 7.00 ± 1.732 | 7.50 ± 4.950 | 7.00 | 4.70 ± 4.373 | 7.00 ± 3.000 | 5.56 ± 6.044 | 2.00 ± 1.871 |
| Week 1 | 4.90 ± 5.021 | 5.41 ± 4.159 | 4.00 | 3.80 ± 3.347 | 6.33 ± 3.215 | 6.00 ± 7.071 | 7.00 | 3.90 ± 3.542 | 4.67 ± 2.887 | 6.00 ± 5.809 | 1.89 ± 1.764 |
| Week 4 | 5.11 ± 5.278 | 5.23 ± 3.337 | 4.00 | 3.00 ± 2.449 | 9.00 ± 1.732 | 7.00 ± 5.657 | 7.00 | 4.40 ± 4.248 | 6.33 ± 1.528 | 5.22 ± 4.631 | 1.56 ± 2.297 |
| Week 8 | 5.89 ± 5.231 | 5.00 ± 4.427 | 5.00 | 4.40 ± 2.881 | 8.33 ± 0.577 | 5.50 ± 3.536 | 7.00 | 3.70 ± 3.945 | 4.67 ± 3.215 | 5.11 ± 4.859 | 1.00 ± 1.118 |
| Week 12 | 6.33 ± 5.679 | 5.05 ± 3.905 | 6.00 | 3.60 ± 3.286 | 6.33 ± 1.528 | 4.50 ± 4.950 | 7.00 | 3.10 ± 4.358 | 5.00 ± 1.000 | 5.22 ± 5.019 | 1.33 ± 1.581 |
The TIS was the sum of all 6 improvement scores where higher score indicates worse status (PhGA \[from the MDAAT, 0-20 scale\], PtGA \[0-10 scale\], MMT \[0-35 scale\], HAQ-DI \[0-10 scale\], muscle enzymes \[0-7.5 scale\], and extramuscular global assessment \[0-20 scale\]) associated with the change in each core set measure. A total improvement score between 0 and 100 corresponded to the degree of improvement, with higher scores corresponding to a greater degree of improvement: of ≥20 represented minimal improvement, a score of ≥40 represented moderate improvement, and a score of ≥60 represented major improvement.
| Units on a scale | Placebo (Stage 3) | PF-06823859 600 mg IV (Stage 3) |
|---|---|---|
| Week 4 | 25.83 (13.15 to 38.52) | 36.67 (23.98 to 49.35) |
| Week 8 | 36.67 (23.38 to 49.95) | 49.17 (35.88 to 62.45) |
| Week 12 | 36.94 (21.93 to 51.96) | 56.39 (41.38 to 71.40) |
PhGA: assessment of the severity of disease by the physician. The physician used the visual analog scale and put a mark on 0 cm (best) -10 cm (worst) scale where higher score indicated worse status. EmGA: overall evaluation of disease activity in all extramuscular systems using visual analog scale 0 cm (best) -10 cm (worst) scale where higher score indicated worse status.
| Centimeter (cm) | Placebo (Stage 3) | PF-06823859 600 mg IV (Stage 3) |
|---|---|---|
| PhGA Week 4 | -1.00 (-1.89 to -0.11) | -1.68 (-2.57 to -0.79) |
| PhGA Week 8 | -1.65 (-2.80 to -0.51) | -2.76 (-3.90 to -1.61) |
| PhGA Week 12 | -2.05 (-3.56 to -0.55) | -3.40 (-4.90 to -1.90) |
| Extramuscular Global Assessment Week 4 | -1.02 (-2.07 to 0.03) | -1.55 (-2.60 to -0.49) |
| Extramuscular Global Assessment Week 8 | -1.91 (-2.80 to -1.01) | -2.48 (-3.38 to -1.58) |
| Extramuscular Global Assessment Week 12 | -1.59 (-2.64 to -0.53) | -2.81 (-3.87 to -1.76) |
PtGA: assessment of the severity of disease by the participant/participant's guardian, using a visual analog scale from 0 mm (no evidence of disease activity) to 100 mm (extremely active or severe disease activity). Higher score indicated worse status.
| Millimeter (mm) | Placebo (Stage 3) | PF-06823859 600 mg IV (Stage 3) |
|---|---|---|
| PtGA Week 4 | -18.29 (-31.78 to -4.79) | -17.88 (-30.75 to -5.00) |
| PtGA Week 8 | -16.81 (-29.88 to -3.73) | -32.60 (-45.85 to -19.35) |
| PtGA Week 12 | -14.04 (-25.91 to -2.17) | -43.81 (-55.68 to -31.95) |
Manual Muscle Testing-8 designated muscle groups (MMT-8): was a set of 8 designated muscles tested unilaterally generally on right side (left side used unless right side cannot be used). Potential score range was from 0 to 80, where higher scores denoted better health status. HAQ-DI: contained eight sections (including dressing \& grooming, arising, eating, walking, hygiene, grip, reach, and activities). Each section had multiple questions that the participant used to rank their functionality and ranged from 0 to 3 where 0 = without any difficulty and 3 = unable to do. For each participant, the average ranking was calculated for each of the eight sections. HAQ-DI had a score range of 0 to 3, where higher score reflected worse status.
| Units on a scale | Placebo (Stage 3) | PF-06823859 600 mg IV (Stage 3) |
|---|---|---|
| MMT8 - Derived Week 4 | 7.76 (1.37 to 14.16) | 8.24 (1.84 to 14.63) |
| MMT8 - Derived Week 8 | 12.14 (4.60 to 19.68) | 15.24 (7.70 to 22.78) |
| MMT8 - Derived Week 12 | 11.65 (2.29 to 21.01) | 21.24 (11.87 to 30.60) |
| HAQ01-HAQ-DI Week 4 | -0.03 (-0.24 to 0.18) | -0.20 (-0.39 to 0.00) |
| HAQ01-HAQ-DI Week 8 | 0.00 (-0.28 to 0.28) | -0.38 (-0.64 to -0.11) |
| HAQ01-HAQ-DI Week 12 | -0.06 (-0.40 to 0.28) | -0.52 (-0.84 to -0.19) |
The LS mean (with 90% CI) of CSM of the TIS (aldolase and creatine kinase) at weeks 4, 8, 12 were presented.
| Units per litre (U/L) | Placebo (Stage 3) | PF-06823859 600 mg IV (Stage 3) |
|---|---|---|
| Aldolase Week 4 | -0.19 (-1.34 to 0.96) | -3.09 (-4.25 to -1.92) |
| Aldolase Week 8 | -1.31 (-2.45 to -0.16) | -3.57 (-4.74 to -2.40) |
| Aldolase Week 12 | -0.66 (-2.18 to 0.86) | -3.20 (-4.76 to -1.64) |
| Creatine Kinase Week 4 | -37.96 (-119.16 to 43.24) | -157.48 (-238.68 to -76.28) |
| Creatine Kinase Week 8 | -70.96 (-137.03 to -4.90) | -175.93 (-241.99 to -109.86) |
| Creatine Kinase ) Week 12 | -39.85 (-125.71 to 46.01) | -185.77 (-273.92 to -97.62) |
Collected over Up to Week 40. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/45 (2.2%) | 3/45 (6.7%) | 22/45 (48.9%) |
| PF-06823859 150 mg IV | 0/17 (0%) | 0/17 (0%) | 13/17 (76.5%) |
| PF-06823859 600 mg IV | 1/47 (2.1%) | 4/47 (8.5%) | 18/47 (38.3%) |
| Total | 1/75 (1.3%) | 5/75 (6.7%) | 45/75 (60%) |
| Event | Placebo | PF-06823859 150 mg IV | PF-06823859 600 mg IV | Total |
|---|---|---|---|---|
| CytopeniaBlood and lymphatic system disorders | 1/45 | 0/17 | 0/47 | 1/75 |
| LeukopeniaBlood and lymphatic system disorders | 1/45 | 0/17 | 1/47 | 1/75 |
| Ocular icterusHepatobiliary disorders | 1/45 | 0/17 | 0/47 | 1/75 |
| Haemophagocytic lymphohistiocytosisImmune system disorders | 1/45 | 0/17 | 0/47 | 1/75 |
| Humerus fractureInjury, poisoning and procedural complications | 1/45 | 0/17 | 1/47 | 1/75 |
| Blood bilirubin increasedInvestigations | 1/45 | 0/17 | 0/47 | 1/75 |
| Hepatic enzyme increasedInvestigations | 1/45 | 0/17 | 0/47 | 1/75 |
| Central nervous system lesionNervous system disorders | 1/45 | 0/17 | 0/47 | 1/75 |
| Colitis microscopicGastrointestinal disorders | 0/45 | 0/17 | 1/47 | 1/75 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/45 | 0/17 | 1/47 | 1/75 |
| Event | Placebo | PF-06823859 150 mg IV | PF-06823859 600 mg IV | Total |
|---|---|---|---|---|
| HeadacheNervous system disorders | 7/45 | 3/17 | 6/47 | 15/75 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/45 | 2/17 | 3/47 | 5/75 |
| PruritusSkin and subcutaneous tissue disorders | 5/45 | 1/17 | 1/47 | 6/75 |
| FatigueGeneral disorders | 4/45 | 1/17 | 1/47 | 6/75 |
| SARS-CoV-2 test positiveInvestigations | 4/45 | 0/17 | 1/47 | 4/75 |
| Upper respiratory tract infectionInfections and infestations | 1/45 | 0/17 | 4/47 | 5/75 |
| NauseaGastrointestinal disorders | 2/45 | 0/17 | 3/47 | 5/75 |
| SinusitisInfections and infestations | 3/45 | 1/17 | 0/47 | 4/75 |
| DiarrhoeaGastrointestinal disorders | 0/45 | 1/17 | 3/47 | 4/75 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/45 | 1/17 | 0/47 | 1/75 |
The safety analysis population included all participants who had received at least 1 dose of study drug or placebo.
| Age, Continuous(years) | (Stage 1) Placebo | (Stage 1) PF-06823859 600 mg Intravenous (IV) | (Stage 2) Placebo | (Stage 2) PF-06823859 150 mg IV | (Stage 2) PF-06823859 600 mg IV | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 50.20 ± 14.054 | 54.41 ± 13.154 | 42.00 | 51.60 ± 15.726 | 45.67 ± 23.714 | 64.00 ± 1.414 | 44 | 53.90 ± 10.999 | 47.00 ± 13.115 | 47.44 ± 12.126 | 42.44 ± 16.697 | 50.63 ± 13.793 |
| Age, Customized(Participants) | (Stage 1) Placebo | (Stage 1) PF-06823859 600 mg Intravenous (IV) | (Stage 2) Placebo | (Stage 2) PF-06823859 150 mg IV | (Stage 2) PF-06823859 600 mg IV | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18-64 Years | 8 | 18 | 1 | 4 | 2 | 1 | 1 | 8 | 3 | 8 | 8 | 62 |
| 65-84 Years | 2 | 4 | 0 | 1 | 1 | 1 | 0 | 2 | 0 | 1 | 1 | 13 |
| >=85 Years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | (Stage 1) Placebo | (Stage 1) PF-06823859 600 mg Intravenous (IV) | (Stage 2) Placebo | (Stage 2) PF-06823859 150 mg IV | (Stage 2) PF-06823859 600 mg IV | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 9 | 20 | 1 | 5 | 3 | 2 | 1 | 10 | 2 | 6 | 7 | 66 |
| Male | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 9 |
| Ethnicity (NIH/OMB)(Participants) | (Stage 1) Placebo | (Stage 1) PF-06823859 600 mg Intravenous (IV) | (Stage 2) Placebo | (Stage 2) PF-06823859 150 mg IV | (Stage 2) PF-06823859 600 mg IV | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 3 | 2 | 13 |
| Not Hispanic or Latino | 8 | 20 | 0 | 5 | 2 | 2 | 1 | 9 | 2 | 6 | 7 | 62 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | (Stage 1) Placebo | (Stage 1) PF-06823859 600 mg Intravenous (IV) | (Stage 2) Placebo | (Stage 2) PF-06823859 150 mg IV | (Stage 2) PF-06823859 600 mg IV | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 9 | 20 | 1 | 5 | 3 | 2 | 1 | 9 | 3 | 8 | 8 | 69 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Multiracial | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Not reported | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jan 2018 to primary completion in May 2022, 52 months.
Results were first posted in Sep 2023, 1 year 3 months after primary completion.
Of 19 phase 2 interventional studies under Dermatomyositis, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 52. This study's 52 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dazukibart